for people ages 40 years and up (full criteria)
at La Jolla, California and other locations
study started
estimated completion
Principal Investigator
by Kimberly Hong



The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with preserved ejection fraction and obesity.

Official Title

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT)


The study will continue until approximately 52 weeks after the last participant is randomized. The maximum duration of an individual's participation is estimated to be 120 weeks and will depend on duration of study enrollment.


Obesity, Heart Failure With Preserved Ejection Fraction, Heart Failure with Preserved Ejection Fraction (HFpEF), Heart Failure, Tirzepatide


You can join if…

Open to people ages 40 years and up

  • Have a diagnosis of stable heart failure (NYHA class II-IV) and left ventricular ejection fraction (LVEF) ≥50%
  • Elevated NT-proBNP (N-terminal pro B-type natriuretic peptide) > 200 pg/ml for participants without atrial fibrillation (AF), or >600 picogram/milliliter (pg/ml) for participants with AF, Structural heart disease (Left atrial enlargement) or Elevated left ventricular filling pressure
  • Estimated glomerular filtration rate (eGFR) <70 milliliter (ml)/minute (min)/1.73m² at screening, or HF decompensation within 12 months of screening,
  • Stable dose of heart failure medications within 4 weeks of screening
  • Body mass index (BMI) ≥30 kilograms per meter squared (kg/m²)
  • 6MWD 100-425m
  • KCCQ CSS ≤80

You CAN'T join if...

  • Have had a major cardiovascular event within the last 90 days of screening
  • Have had acute decompensated heart failure within 4 weeks of screening
  • Have non cardiac causes of functional impairment such as pulmonary arterial hypertension (PAH), severe chronic obstructive pulmonary disease (COPD), anemia, thyroid disease, musculoskeletal disease or orthopedic conditions
  • Presence of cardiac amyloidosis, cardiac accumulation disease, cardiomyopathy and severe valvular hear disease
  • HbA1c ≥9.5% or uncontrolled diabetes
  • History of proliferative diabetic retinopathy or diabetic maculopathy
  • Have a history of pancreatitis
  • eGFR <15 mL/min/1.73 m² or requiring dialysis at screening


  • University of California San Diego - La Jolla accepting new patients
    La Jolla California 92037 United States
  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center accepting new patients
    Torrance California 90502 United States

Lead Scientist at UCSD

  • Kimberly Hong
    Assistant Clinical Professor, Medicine, Vc-health Sciences-schools. Authored (or co-authored) 44 research publications


accepting new patients
Start Date
Completion Date
Eli Lilly and Company
Phase 3 research study
Study Type
Expecting 700 study participants
Last Updated